Which medication is associated with an increased risk of postpartum depression?

Methyldopa is associated with an increased risk of postpartum depression due to its effects on the central nervous system. This medication, commonly used to manage hypertension in pregnant women, can lead to mood alterations and depressive symptoms. The mechanism by which methyldopa may contribute to postpartum depression is not entirely understood, but it may involve alterations in neurotransmitter levels and central sympathetic inhibition, which can impact mood regulation.

In contrast, hydrochlorothiazide, metoprolol, and amlodipine do not have established links to postpartum depression. Hydrochlorothiazide, as a diuretic, primarily affects fluid balance and does not have a direct impact on mood. Metoprolol, a beta-blocker, is used for cardiovascular conditions and does not significantly influence depressive disorders. Amlodipine, a calcium channel blocker, also does not have a recognized association with increased depression risk. Therefore, the choice of methyldopa as the medication associated with heightened risk for postpartum depression is supported by the evidence regarding its pharmacological effects and the impact on mood.